Impact of Semaglutide on Limb Events: A Meta-Analysis of Randomized Controlled Trials - PubMed
3 months ago
- #Meta-Analysis
- #Semaglutide
- #Peripheral Artery Disease
- Semaglutide significantly reduces the risk of limb events (LEs) in individuals with type 2 diabetes and/or obesity.
- The meta-analysis included 19 randomized controlled trials with 51,557 participants.
- LEs included revascularizations, amputations, and PAD progression, with a pooled odds ratio (OR) of 0.70 (95% CI 0.60-0.82).
- Benefits were consistent across patient subgroups, formulations (oral or injectable), and regardless of SGLT2 inhibitor use.
- No significant effect modification was found by age, BMI, HbA1c, follow-up duration, or SGLT2i use.
- Semaglutide reduced PAD-related events by about 30% compared to other treatments.